Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amy K. Kim has a total of 184 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cell-free DNA fragmentomes for noninvasive detection of liver cirrhosis and other diseases

    by Akshaya V. Annapragada, Zachariah H. Foda, Hope Orjuela, Carter Norton, Shashikant Koul, Noushin Niknafs, Sarah Short, Keerti Boyapati, Adrianna Bartolomucci, Dimitrios Mathios, et al.

    Accessible liquid biopsies, including analyses of genome-wide cell-free DNA (cfDNA) fragmentation, are emerging for early detection of cancer but remain largely unexplored in other diseases. Here, we used whole-genome sequencing to examine cfDNA fragmentomes in 1576 individuals, including those with liver disease or with other morbidities such as vascular, autoimmune, and neurodegenerative conditions. As a prototype for disease-specific cfDNA fragmentomic biomarkers, we developed a machine learning classifier that detected early liver disease, advanced fibrosis, and cirrhosis with high sensitivity in separate discovery ( n = 423) and validation cohorts ( n = 221) and had limited cross-reactivity for other diseases. Genome-wide fragmentome and methylome analyses revealed liver-derived and immune-mediated changes in cfDNA in the circulation of individuals affected with liver disease. Fragmentomic changes were also observed across a range of other human morbidities and reflected disease-specific changes in the circulation. A machine learning model using cfDNA fragmentomes predicted overall survival in separate morbidity discovery ( n = 571) and validation cohorts ( n = 231). These analyses demonstrate the connection between cfDNA fragmentomes and an individual’s physiologic state and provide previously unrecognized possibilities for cfDNA liquid biopsies across human disease.


  • Clinical utilization of testing for cell-free DNA in hepatocellular cancer

    by Jasmine J. Wang, Yi-Te Lee, Amy K. Kim, Augusto Villanueva, Amit G. Singal, Ju Dong Yang

    HCC is one of the leading causes of cancer-related death globally. HCCs are often diagnosed in advanced stages, and most patients are not eligible for curative treatments. Semiannual abdominal ultrasound with serum alpha-fetoprotein is the current recommended surveillance strategy; however, it has suboptimal sensitivity and implementation, thereby lowering its effectiveness for early-stage HCC detection. Further, post-treatment monitoring of HCC recurrence or progression is not tailored to tumor aggressiveness. These failures highlight critical unmet needs, which can be addressed by novel biomarkers that enable early detection and guide individualized surveillance and post-treatment follow-up for HCC, ultimately leading to improved outcomes in this disease. Cell-free DNA (cfDNA), consisting of small fragments of DNA released from tumor and normal cells into the bloodstream, reflects tumor-specific molecular alterations and has emerged as a promising noninvasive biomarker. This review summarizes recent advances in cfDNA applications in HCC, including risk stratification, early detection, prognostication, and minimal residual disease assessment. Among them, cfDNA has made the most progress in early detection. cfDNA assays, combined with clinical and serum parameters, demonstrate sensitivity noninferior or superior to ultrasound for detecting early HCC, with larger phase 3 validation studies ongoing. In contrast, the use of cfDNA for risk stratification, prognostication, and minimal residual disease detection remains in the early stages of clinical development. Future multicenter studies with standardized methodologies and rigorous validation will be essential to translate cfDNA into routine clinical practice for the management of HCC.


  • Open Access

    Supplementary Tables from Detecting Liver Cancer Using Cell-Free DNA Fragmentomes

    by Zachariah H. Foda, Akshaya V. Annapragada, Kavya Boyapati, Daniel C. Bruhm, Nicholas A. Vulpescu, Jamie E. Medina, Dimitrios Mathios, Stephen Cristiano, Noushin Niknafs, Harry T. Luu, et al.

    Supplementary Table S1 shows Clinical information of US/EU patients analyzed. Supplementary Table S2 is a summary of whole genome cfDNA analyses. Supplementary Table S3 shows clinical information of Hong Kong patients analyzed. Supplementary Table S4 shows the lowest scoring transcription factors in US/EU cohort samples. Supplementary Table S5 lists the plasma volume and cfDNA amounts used in genomic libraries.

  • Open Access

    Supplementary Figures S1-S14 from Detecting Liver Cancer Using Cell-Free DNA Fragmentomes

    by Zachariah H. Foda, Akshaya V. Annapragada, Kavya Boyapati, Daniel C. Bruhm, Nicholas A. Vulpescu, Jamie E. Medina, Dimitrios Mathios, Stephen Cristiano, Noushin Niknafs, Harry T. Luu, et al.

    Supplementary Figure S1 shows contributions of individual genomic regions to the final trained DELFI surveillance model. Supplementary Figure S2 shows DELFI scores in individuals without cancer by age and sex. Supplementary Figure S3 shows DELFI scores in high-risk individuals without cancer across racial or ethnic groups. Supplementary Figure S4 shows DELFI scores in cirrhotic patients in relation to severity. Supplementary Figure S5 shows DELFI scores in individuals in relation to BMI. Supplementary Figure S6 Shows Performance of alternative DELFI models. Supplementary Figure S7 shows Correlation between rank ordered DELFI. Supplementary Figure S8 shows DELFI scores in patients with HCC were related to tumor characteristics. Supplementary Figure S9 shows DELFI scores in by etiology of underlying liver disease. Supplementary Figure S10 shows the DELFI score in patients with HCC is correlated to AFP levels. Supplementary Figure S11 shows the correlation of fragmentation profiles. Supplementary Figure S12 shows Genome wide fragmentation profiles in the Hong Kong validation cohort Supplementary Figure S13 shows chromosomal copy number in Hong Kong cohort. Supplementary Figure S14 shows the implementation of DELFI in liver cancer screening.

  • Open Access

    A fixation-compatible protocol for intracellular and surface marker-based detection of circulating tumor cells in hepatocellular carcinoma

    by Boqun Zhu, Kanako Yoshida, Harry Luu, Hao Zhang, Joseph V. Passero, Kathy Liu, Selena Y. Lin, Ying-Hsiu Su, Hyunsoo Song, James P. Hamilton, et al.

    Circulating tumor cell (CTC) detection in hepatocellular carcinoma (HCC) is limited not only by the rarity of CTCs but also by a heavy reliance on cell surface markers such as EpCAM, which are variably expressed or lost during tumor progression. Detecting intracellular markers, such as cytokeratin offers an important complementary and comprehensive strategy but remains technically limited in flow cytometry due to the need for fixation and permeabilization, which often lead to cell loss and surface epitope damage. In this study, we systematically evaluated the feasibility of using fixed samples for flow cytometry, using HepG2 cells, PBMCs, and CTCs from patients with HCC. Our results demonstrate that fixation enabled intracellular staining without compromising cell surface marker detection, even after short-term storage at 4 °C and long-term storage at -80 °C. Fixed samples, particularly fixed unfrozen, exhibited comparable staining performance to fresh samples with only a 7–10% reduction in cell recovery. Clinical validation in HCC patients confirmed successful CTC detection, and tumor-specific CTNNB1 mutations were identified in CTC-derived DNA but not in matched plasma cfDNA. These findings support fixed CTC sample workflows as a reliable and practical approach for CTC analysis in HCC.

  • Open Access

    Environmental exposures and the risk of hepatocellular carcinoma

    by Divya Rayapati, Katherine A. McGlynn, John D. Groopman, Amy K. Kim

    The global epidemiology of HCC is shifting due to changes in both established and emerging risk factors. This transformation is marked by an emerging prevalence of metabolic dysfunction–associated steatotic liver disease (MASLD) and type 2 diabetes, alongside traditional risks such as viral hepatitis (HBV and HCV), and exposure to chemical agents like aflatoxin, alcohol, tobacco, and air pollution. This review examines how environmental exposures and evolving liver pathology, exacerbated by lifestyle and metabolic conditions, are contributing to the rising worldwide incidence of HCC. Effective prevention strategies must not only address traditional risk factors through vaccination and therapeutic measures but also confront metabolic and socioeconomic disparities through comprehensive public health efforts. As the burden of liver cancer continues to grow, particularly in resource-limited settings, an expansive and inclusive approach is vital for mitigating its impact across diverse populations.


  • Open Access

    Supplementary Figure 1 from Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC

    by Mari Nakazawa, Mike Fang, Tyrus Vong, Jane Zorzi, Paige Griffith, Robert A. Anders, Kiyoko Oshima, Amy K. Kim, Jacqueline Laurin, Kelly J. Lafaro, et al.

    S1. Flow diagram depicting inclusion and exclusion criteria for current study

  • Open Access

    Supplementary Figure 1 from Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC

    by Mari Nakazawa, Mike Fang, Tyrus Vong, Jane Zorzi, Paige Griffith, Robert A. Anders, Kiyoko Oshima, Amy K. Kim, Jacqueline Laurin, Kelly J. Lafaro, et al.

    S1. Flow diagram depicting inclusion and exclusion criteria for current study

  • Top Cited Papers

    Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: The multicenter VITALITY study

    by Parissa Tabrizian, Matthew L. Holzner, Veeral Ajmera, Amy K. Kim, Kali Zhou, Gabriel T. Schnickel, Kelly Torosian, Maarouf Hoteit, Rebecca Marino, Michael Li, et al.